Clinical trials: Tumor Gastric
Gastric Cancer
Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
This study intends to explore the value of 68Ga-FAPI-04 and 18F-FDG PET/CT in the evaluation of treatment response to neoadjuvant chemotherapy(NAC) for patients with locally advanced gastric cancer(LAGC).
- Trial name
- NCT05140746
- Testing
- 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Gastric Cancer
Impact of Preoperative VFA on Intraoperative Adverse Events in Patients Undergoing Laparoscopic Radical Gastrectomy
Preoperative visceral fat area (VFA) is associated with an increased incidence of postoperative complications in gastric cancer (GC). However, the relationship between VFA and intraoperative adverse events (iAEs) remains unclear.
- Trial name
- NCT06506331
- Volunteers
- 490 people
- Sponsor
- Fujian Medical University
Gastric Cancer
Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy
Adjuvant chemotherapy followed by curative gastrectomy for Stage II/III gastric cancer has improved disease free time and survival.
- Trial name
- NJBMR (NCT01905969)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Iwate Medical University
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Advanced Breast Carcinoma, Advanced Colon Carcinoma
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have…
- Conditions
- Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04704661
- Testing
- Biopsy Procedure, Biospecimen Collection, Ceralasertib
- Where
- 23 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Oligometastasis
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic).
- Conditions
- Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Cancer AJCC v7
- Trial name
- NCT03161522
- Testing
- Capecitabine, Chemotherapy, Conventional Surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Gallstones, Gastric Cancer
The Incidence of Gallstones After Gastric Cancer Surgery
Through previous clinical observations and literature, we found that the incidence of gallstones in patients after gastric cancer radical resection was significantly higher than that in the normal population (4%).
- Trial name
- NCT04250402
- Testing
- Resection
- Where
- 2 sites in China
- Volunteers
- 1,019 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Gastric Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy of ipatasertib in combination with oxaliplatin, 5-fluorouracil, and leucovorin (modified FOLFOX6 [mFOLFOX6]) chemotherapy in…
- Trial name
- NCT01896531
- Testing
- 5-Fluorouracil, Ipatasertib, Leucovorin
- Where
- 34 sites in United States, France and 9 more
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or…
- Trial name
- NCT07362186
- Testing
- LM-108 in combination with Toripalimab, Paclitaxel injection intravenous infusion
- Where
- China
- Volunteers
- 400 people
- Sponsor
- LaNova Medicines Limited
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Endoscopy, Digestive System, Esophageal Neoplasms
Endoscopic Submucosal Dissection in Upper Gastrointestinal Canal With HybridKnife
Endoscopic submucosal dissection (ESD) is a relatively new modality for the treatment of superficial gastrointestinal neoplasia and especially in the diagnosis and treatment of submucosal tumors.
- Conditions
- Endoscopy, Digestive System, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT01185483
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Gastric Cancer
Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer
The primary objective is to determine the tumor response rate of bi-weekly docetaxel plus 24-hour infusion of high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.
- Trial name
- NCT00155883
- Testing
- Taxteral, 5-Fluorouracil, Leucovorin
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer, Gastric Cancer
Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
The purposes of this study are to collect and store samples including blood, normal and tumor tissue from patients with colorectal cancer or gastric cancer, to collect and store samples including blood and/or normal…
- Conditions
- Colorectal Cancer, Gastric Cancer, Inflammatory Bowel Diseases, Gastric Ulcer
- Trial name
- NCT03972956
- Testing
- No intervention will be given to patients.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Renmin Hospital of Wuhan University
Gastric Cancer
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
For second-line chemotherapy for metastatic gastric cancer, single-agent irinotecan is the standard treatment. Anthracyclines are active but lack well designed investigations.
- Trial name
- NCT04358341
- Testing
- Irinotecan, DOXOrubicin Liposome Injection, 5fluorouracil
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Advanced Solid Tumors
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
- Trial name
- NCT06730750
- Testing
- BMS-986490, Bevacizumab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 360 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer (GC), Colorectal Cancer
Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer
The goal of this observational study is to learn whether a computer program can suggest cancer treatments that match expert recommendations for people with gastrointestinal cancer (cancer of the pancreas, stomach, or colon and…
- Conditions
- Gastric Cancer (GC), Colorectal Cancer, Pancreatic Cancer
- Trial name
- KITuKo (NCT07592338)
- Testing
- Treatment recommendation according to official German cancer guideline, Treatment recommendation of a LLM, Treatment recommendation of a multidisciplinary tumor board
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
Gastric Cancer
Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk
The Systemic Oxidative Stress Score (SOSS) , a comprehensive score reflecting the oxidative stress conditions in the microenvironment, can independently and effectively predict tumor burden and long-term prognosis in GC patients.
- Trial name
- NCT06337279
- Where
- China
- Volunteers
- 3,820 people
- Sponsor
- Fujian Medical University
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer
RATIONALE: Analgesics, antiemetics, steroids, and radiation therapy are effective in helping to control symptoms caused by cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer, Nausea and Vomiting
- Trial name
- NCT00978549
- Testing
- docetaxel, steroid therapy, questionnaire administration
- Where
- 8 sites in United Kingdom
- Volunteers
- 320 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.